Answers are grounded in this paper and cite their sources.
Hypertension is a rapidly growing epidemic in Sub-Saharan Africa characterized by extremely low rates of diagnosis, treatment, and control, necessitating locally adapted, cost-effective public health and management strategies.
Ischemic heart disease is the leading cause of death globally, accounting for almost 9 million deaths annually as of 2015.1 According to World Health Organization (WHO) data, the number of deaths as a result of ischemic heart disease has increased by almost 2 million per year since 2000.1 In developing regions around the world, as defined by World Bank groupings, cardiovascular disease is now the number one killer in all regions with the exception of sub-Saharan Africa, where it ranks second. However, with sub-Saharan Africans above the age of 30, cardiovascular disease again rises to the top as the leading cause of death.2 The WHO identifies hypertension as the leading risk factor for cardiovascular disease.3 The incidence of hypertension globally was around 1 billion people in 2008, an increase from 600 million in 1980.4 Across all WHO regions, including the Americas, Africa has the highest prevalence of hypertension where 46% of the entire population over 25 years of age is estimated to be hypertensive. In the INTERHEART Africa study, we learned that the age at which sub-Saharan Africans present with first myocardial infarction is significantly younger than any other global region using comparison data from the global INTERHEART study. Further, 5 modifiable risk factors, with hypertension as the most profound, is attributed to 89.2% of acute myocardial infarctions in sub-Saharan Africans.5,6 This problem is projected to continue to worsen and without intervention could become epidemic.5 Given all of this, the WHO has put forth a Global Action Plan including the following goals by 2020: (i) a 25% relative reduction in the prevalence of raised blood pressure or contain the prevalence of raised blood pressure, according to national circumstances; (ii) a 30% relative reduction in mean population intake of salt/sodium; at least 50% of eligible people receive drug therapy and counseling to prevent heart attacks and strokes; (iii) an 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major noncommunicable diseases.7 In this discussion, it becomes essential to understand how hypertension is currently managed in sub-Saharan Africa, the challenges surrounding the illness, and how these might be mitigated. A large systematic review found that less than 40% of hypertensives in sub-Saharan Africa were diagnosed as such, less than 30% of those diagnosed were receiving medical treatment, and less than 20% of those had good control with blood pressures in the normal range.8 Dr. Twagirumukiza of Rwanda published a robust algorithm on how hypertension management might be approached both at the community and health center level. He proposes early identification, trial of nonpharmacologic therapy (including reduced sodium intake, cessation of smoking, amongst others), and affordability-based pharmacologic regimens. The backbone of medical therapy in his proposal is thiazide diuretics at low doses to prevent side effects that might go unnoticed at what we consider more effective and typical doses. Other therapies in the algorithm include direct alpha blockers and reserpine or rauwolfia extracts—medications not frequently used to manage hypertension in the United States.9 Others have compiled different factors that contribute to poor control of hypertension in sub-Saharan Africa. The reasons are compelling and not easily overcome. These include low compliance, lack of health insurance, lack of preventive strategies, affordability (in Malawi it costs over 18 days’ wages for a monthly supply of a generic and standardized secondary prevention regimen), lack of availability, shortage of health workers/centers, and poverty in general.10 While we face similar challenges in the United States in name, the scale and complexity of these same issues in sub-Saharan Africa is incomparable. Some proposed methods of addressing these issues include calling on international aid, health funding bodies, public health initiatives (including but not limited to food manufacturing to regulate salt levels), development of national hypertension organizations, and governmental investments in building more robust health systems.11 In our personal experience at the Queen Elizabeth Central Hospital in Blantyre, Malawi, in the spring of 2017, we learned that despite daily struggles we can only minimally understand, Malawians truly do care about hypertension management. Despite the silent nature of hypertension, easily forgotten in a population exposed to extreme poverty and one of the highest HIV prevalence in the world, we encountered many who invested significant time and effort to seek treatment. We met elderly and frail patients who travelled hours for medication refills and blood pressure checks, often finding long lines and limited resources. Medication regimens were fickle at best, with frequent changes based on availability and cost. Arranging follow-up visits was complicated given accessibility to clinics and resource allocation. Despite these hurdles, it was remarkable to see the crowds of Malawians seek care for hypertension, may it be at the hospital or travelling clinics in remote villages. As outsiders encountering these populations, through philanthropy or otherwise, we need to restructure our typical approach to hypertension management into one that is more appropriately aligned with the local environment. In doing so, we may best help this large group of people in need while we continue to anticipate and hope for more robust solutions. This frameshift might include relying on less trained workers being deployed out to communities in need. Local medical students might fit this role well. Treatment algorithms should take into consideration local resources in a concerted effort to provide cost-effective medications for long intervals. Efforts should also focus on increasing availability of voluntary blood pressure monitoring with low cost devices. Lastly, continued public health initiatives to build and expand patient education on the importance of hypertension management are vital. Such changes are easy to propose in writing but require large scale buy-in at the level of the patient, provider, and administration. We applaud the leadership of the WHO to identify actionable items and develop a sound plan to begin making a dent in this widespread disease. The authors declared no conflict of interest.
No takes yet. Share an insight, caveat, or question.
Yoruk et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: